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Huntington’s disease
Source: https://ghr.nlm.nih.gov
Gusella & MacDonald, 2009
Clinical manifestation
MOTOR SIGNS COGNITIVE IMPAIRMENT
Executive functions impairment
Delayed acquisition of new motor skills
Cognitive inflexibility
NEUROENDOCRINE 
ALTERATIONS
Involuntary weight loss 
Muscle wasting
Metabolic dysfunction
Endocrine alterations
BEHAVIOURAL 
ALTERATIONS
Depression                        
Dysphoria                          
Irritability
Obsessive compulsive behaviour
Apathy
Anxiety
Chorea
Bradykinesia                          
Incoordination
Myoclonus                              
Motor impersistence
Incoordination
Impairment of fine 
motor skills
Gait and postural 
instability
Dysphagia
Dysarthria
Dystonia
Causes of death
REGISTRY of the European Huntington's Disease Network
Rodrigues et al, 2017 Heemsker & Ross, 2012
Cause of death N %
Penumonia 81 55.1
Suffocation 6 4.1
Pulmonary embolism 6 4.1
Cachexia 11 7.5
Cardiac diseases 16 10.9
Other neurological
diseases
3 2.0
Shock/sepsis 7 4.8
Suicide 2 1.4
Euthanasia 5 3.4
Other causes 10 6.8
38/81 with autopsy
16 aspiration
17 possible aspiration
5 primary infectious


DOSS scores derived from clinical swallow assessment 
(Bedside Swallowing Assessment Scale + Water swallow test)
Gap of knowledge and Clinical relevance
No data are available on the prevalence and the characteristics of
dysphagia in different stages of HD, as assessed by instrumental
evaluation of swallowing
These data may be relevant to define the best timing of swallowing first
assessment and re-assessment in this population
Research questions
• Does dysphagia affect patients with HD already at an early disease
stage?
• Do signs of dysphagia differ among the disease stages?
• Are there neurological clinical factors that can suggest the presence of
dysphagia?
Methods Study design
Cross-sectional study with prospective consecutive recruitment
Approved by the Ethics Committees of the Luigi Sacco Hospital and the
IRCCS Istituto Auxologico Italiano
Written informed consent was obtained from participants or their
caregivers
Methods Patients
43 genetically confirmed HD patients (CAG39)
18M, 25F
Age 57 ± 2 years (27-78)
CAG 43.5 ± 0.6 (39-59)
Onset 49.2 ± 1.9 years (23-71)
Disease duration 7.9 ± 0.7 years (1-19)
Exclusion criteria History of head and neck cancer, other neurological
diseases, self-reported or documented dysphagia prior to HD diagnosis
Methods Neurological assessment
Disease staging based on UHDRS Functional Capacity
score 13-7 Early 20 patients (Shoulson-Fahn stage 1-2)
score 6-4 Moderate 10 patients (Shoulson-Fahn stage 3)
score 3-0 Advanced 13 patients(Shoulson-Fahn stage 4-5)
Shoulson & Fahn, 1979; Nóbrega & de Almeida, 2018
Subscale Domain
UHDRS I Motor assessment
UHDRS II Cognitive assessment
UHDRS III Behavioural assessment
UHDRS IV Independence scale
UHDRS V Functional assessment
UHDRS VI Total functional capacity
Unified Huntington's Disease Rating Scale (UHDRS)
Methods Controls
27 age-matched healthy volunteers 
14M, 13F
Age 50.4 ± 3.2 years
Inclusion criteria Age>20 years, no medical history of voice, swallowing, 
gastroenterological, respiratory, neurologic, metabolic, hematologic or 
neoplastic disorders
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Methods Swallowing assessment
Fiberoptic endoscopic examination of swallowing (FEES)
5ml, 10ml, 20ml liquid x 3
5ml, 10ml, 20ml semisolid x 3
½ cracker x 2
Dysphagia severity Dysphagia Outcome and Severity Scale (DOSS)
Swallowing safety Penetration Aspiration Scale (PAS)
Swallowing efficiency Yale Pharyngeal Residue Severity Rating Scale (YPRSRS)
2 independent raters + 3rd rater for disagreements
Rosenbek et al, 1996; O’Neil et al, 1999; Neubauer et al, 2015
Test of Masticating and Swallowing Solids (TOMASS)
Standard ½ cracker (Gran PavesiTM)
Instruction to eat the cracker ‘as quickly as is comfortably possible and when you have 
finished, say your name out loud’
Huckabee et al, 2018
N bites 
N swallows 
N masticatory cycles 
Time
N masticatory cycles / Bite
N swallows / Bite
Time / Bite
Time / Masticatory cycle
Time / Swallow
MEASURES
Methods Swallowing assessment
Mealtime Assessment Scale (MAS)
Observation of consumption of a full typical meal
Methods Swallowing assessment
Pizzorni et al, 2019
SAFETY SCORE
Oral control of the bolus
Residue in the oral cavity
Presence of cough or throat clearing
Voice quality post-swallow
EFFICACY SCORE MEAL DURATION
MinutesFood leakage while chewing
Oral preparation
Ability to complete the meal without
exhorations
Fatigue
% Meal eaten
Amount of food eaten
Methods Data analysis
One-way ANOVA or Kruskal-Wallis test + post-hoc multiple comparisons
test with Bonferroni correction to compare DOSS, PAS, and YPRSRS,
TOMASS, and MAS among controls and patients with different disease
stage
Spearman’s correlation test to correlate dysphagia severity (DOSS) and
disease severity (UHDRS)
Receiver Operating Characteristic curves with area under the curve (AUC)
to test diagnostic accuracy of the UHDRS I (Total Motor scale) to detect
presence of dysphagia
Results
Does dysphagia affect HD patients 
already at an early disease stage?
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(n o rm a l sw a llo w in g )
 d y s p h a g ia  s e v e r ity  s ta g e s  1 -2
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No dysphagia (DOSS ≥6)
Dysphagia (DOSS <6)
Results
Do signs of dysphagia differ among disease stages?
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Silent aspiration (PAS =8)
10% Early stage
10% Moderate-stage
31% Advanced-stage
PA
S
Results
Do signs of dysphagia differ among disease stages?
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Results
Do signs of dysphagia differ 
among disease stages?
Significant differences in derived measures:
✓ Time/Bite Early vs Advanced
✓ Time/Masticatory cycle Early vs Advanced + Moderate vs Advanced
✓ Time/Swallow Early vs Advanced + Moderate vs Advanced
*
TOMASS was not performed for safety reasons in 2 patients in the early
and in the moderate stages and in 5 patients in the advanced stage
Results
Do signs of dysphagia differ among disease stages?
ns
**
*
Results
Are there neurological clinical factors that can suggest the 
presence of dysphagia?
U H D R S  T M S
D
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H D  e a rly
H D  m o d e ra te
H D  a d v a n c e d
S p e a rm a n
r= -0 .6 2 6 2
P < 0 .0 0 0 1
UHDRS I TMS item Spearman r p value
Ocular pursuit -0.4997 0.0006
Saccade initiation -0.5260 0.0003
Saccade velocity -0.5285 0.0003
Dysarthria -0.5435 0.0002
Tongue protrusion -0.4281 0.0042
Finger taps -0.5859 <0.0001
Pronate/supinate hands -0.6051 <0.0001
Luria -0.5276 0.0003
Rigidity-arms -0.4760 0.0013
Bradykinesia-body -0.4250 0.0045
Maximal dystonia -0.4732 0.0014
Maximal chorea -0.2870 0.0620
Gait -0.4996 0.0006
Tandem walking -0.5227 0.0003
Retropulsion pull test -0.4571 0.0021
Results
Are there neurological clinical factors that can suggest the 
presence of dysphagia?
AUC 0.83 (95%CI 0.71-0.96)
UHDRS I TMS ≥37
Sensitivity 82%
Specificity 73% 
1 0 0 %  -  S p e c if ic ity %
S
e
n
s
it
iv
it
y
%
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
T M S 3 7
s e n s it iv ity  8 2 %
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Conclusions
• 30% of patients with HD with early-stage disease exhibit dysphagia during FEES and
10% shows silent aspiration. Thus, swallowing assessment is warranted starting
already at an early stage of HD.
• Except for penetration and aspiration, swallowing did not significantly changed
between the early and the moderate stages. Conversely, both swallowing safety and
efficiency significantly worsened in the advanced stage. Thus, both pulmonary and
nutritional consequences should be strictly monitored at this stage.
• Multidimensional assessment of swallowing is necessary to record changes in both
swallowing safety and efficiency in this population, only partially recorded by FEES.
• Dysphagia severity strongly correlated with the motor function. A UHDRS TMS≥37
can be used as a clinical cut-off for referral to the swallowing team, even in case of
no symptoms.
Future perspectives
• Improve sample size within each disease stage
• Longitudinal study on the evolution of dysphagia in HD
• Impact of early dysphagia management on its health and 
psychosocial consequences
• Treatment possibilities
